Data / Drug companies / Wilshire Pharmaceuticals, Inc.
Wilshire Pharmaceuticals, Inc.: 48 products in the FDA NDC directory, labeler code 52536
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Wilshire Pharmaceuticals, Inc. (labeler code 52536) lists 48 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 48 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 27, 2026.
The request: Watch Wilshire Pharmaceuticals, Inc. (FDA labeler code 52536): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 52536
- Products in commercial distribution
- 48
- Packages
- 57
- Finished drugs by generic name
- 16
- Prescription products
- 48
- Over the counter products
- 0
- Controlled substance products
- Schedule II 7, Schedule III 1, Schedule IV 2
- Flagged as original packager
- 46 of 46 products that carry the flag
- Started marketing in the last 12 months
- 8
- Products with a marketing end date set
- 2
- Earliest marketing start
- May 29, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 43.8% |
| Authorized generics (NDA) | 15 | 31.2% |
| New drug applications (NDA) | 12 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 48 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 11 | 22.9% |
| Tablet, film coated | 7 | 14.6% |
| Kit | 4 | 8.3% |
| Capsule, delayed release | 4 | 8.3% |
| Tablet, delayed release | 3 | 6.2% |
| Suspension | 3 | 6.2% |
| Injection | 3 | 6.2% |
| Capsule, extended release | 3 | 6.2% |
| Capsule, gelatin coated | 3 | 6.2% |
| Powder, for solution | 2 | 4.2% |
| Solution, concentrate | 2 | 4.2% |
| Granule, for suspension | 2 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Azilsartan Medoxomil | 52536-008 | Tablet | New drug applications (NDA) | April 27, 2026 |
| Azilsartan Medoxomil | 52536-004 | Tablet | New drug applications (NDA) | April 27, 2026 |
| Lomustine | 52536-342 | Capsule, gelatin coated | New drug applications (NDA) | April 15, 2026 |
| Lomustine | 52536-341 | Capsule, gelatin coated | New drug applications (NDA) | April 15, 2026 |
| Lomustine | 52536-340 | Capsule, gelatin coated | New drug applications (NDA) | April 15, 2026 |
| PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride | 52536-302 | Powder, for solution | Authorized generics (NDA) | April 15, 2026 |
| Sodium sulfate, potassium sulfate and magnesium sulfate | 52536-177 | Solution, concentrate | New drug applications (NDA) | April 15, 2026 |
| Sodium sulfate, potassium sulfate and magnesium sulfate | 52536-175 | Solution, concentrate | New drug applications (NDA) | April 15, 2026 |
| Dexmedetomidine hydrochloride | 52536-126 | Injection | Generic drugs (ANDA) | January 30, 2025 |
| Dexmedetomidine hydrochloride | 52536-125 | Injection | Generic drugs (ANDA) | January 30, 2025 |
| Verapamil Hydrochloride | 52536-487 | Capsule, extended release | Authorized generics (NDA) | November 26, 2024 |
| Verapamil Hydrochloride | 52536-486 | Capsule, extended release | Authorized generics (NDA) | November 26, 2024 |
| Verapamil Hydrochloride | 52536-485 | Capsule, extended release | Authorized generics (NDA) | November 26, 2024 |
| Enalapril maleate | 52536-401 | Solution | New drug applications (NDA) | April 8, 2024 |
| Baclofen | 52536-600 | Suspension | Authorized generics (NDA) | April 1, 2023 |
| Vancomycin Hydrochloride for Oral Solution | 52536-108 | Kit | Authorized generics (NDA) | March 31, 2023 |
| Vancomycin Hydrochloride for Oral Solution | 52536-107 | Kit | Authorized generics (NDA) | March 31, 2023 |
| Vancomycin Hydrochloride for Oral Solution | 52536-106 | Kit | Authorized generics (NDA) | March 31, 2023 |
| Vancomycin Hydrochloride for Oral Solution | 52536-104 | Kit | Authorized generics (NDA) | March 31, 2023 |
| Isosorbide dinitrate and hydralazine hydrochloride | 52536-006 | Tablet, film coated | Authorized generics (NDA) | April 15, 2022 |
| Dextroamphetamine Sulfate | 52536-530 | Tablet | Generic drugs (ANDA) | August 6, 2021 |
| Dextroamphetamine Sulfate | 52536-520 | Tablet | Generic drugs (ANDA) | August 6, 2021 |
| Dextroamphetamine Sulfate | 52536-515 | Tablet | Generic drugs (ANDA) | August 6, 2021 |
| Erythromycin ethylsuccinate | 52536-132 | Suspension | New drug applications (NDA) | August 24, 2020 |
| Erythromycin | 52536-186 | Tablet, delayed release | Generic drugs (ANDA) | July 22, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.